• Home
  • Search Results

Search Results

Adult (35-64)
2267 studies match your search
Open

Creatine Perimenopause Study

Are you in perimenopause? Are you interested in lifting weights and taking creatine supplements? Do you want to learn more about your body and brain? If so, you may be able to participate in a research study to understand the impact of resistance training and creatine on muscle quality and cognition in perimenopause!

Age & Gender
  • 38 years ~ 60 years
  • Female
Study Interest
  • Eating, Nutrition, and Metabolism
  • Healthy Volunteer or General Population
  • Sexual and/or Reproductive Health
  • and 4 more
Open

Choice and Motivation Study

This study's findings will contribute to a broader understanding of how goal framing and self-regulatory tools can promote sustained engagement in health-related behaviors. Maintaining good health is essential for everyone. By participating in this study, you will help demonstrate the role of motivation in encouraging individuals to take action toward improving their health through health-related behaviors.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Mental and Emotional Health
  • Opinions and Perceptions
  • UNC Students (undergrad, grad, professional)
Coming Soon

Tirzepatide in Obesity-Driven Endometrial Cancer

To determine the anti-proliferative effect of tirzepatide on the endometrium of endometrial cancer (EC) patients .

Age & Gender
  • 18 years ~ 99 years
  • Female
Study Interest
  • Cancer (Uterine (endometrial))
Open

QuantifyHER

This trial seeks to enroll patients diagnosed with HER2-negative (HER2- low or HER2-0)- MBC who are starting treatment with T-DXd. The purpose is to determine if the test used for HER2+ MBC also works for HER2-low MBC. By participating in this trial, you are contributing to information that may improve the care of future patients with HER2-negative (HER2- low or HER2-0)- MBC. This trial does not require additional biopsies. Only tissue left over from a standard-of-care procedure will be used. The study team will access your medical record to review routine imaging test results as well as track your response to your treatment. Your breast cancer care will be managed by your oncologist, and you won't need to interact with the study team for direct care. No extra visits with the study team are required, except possibly for the initial enrollment.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Breast)
Open

Ketorolac for IUD Pain Control

Are you planning on having an IUD placed? If you are already planning to get an IUD, this study gives the chance to receive extra pain medication during insertion. Everyone will receive standard pain medication, and 2/3 of volunteers will receive extra. We are looking to see if giving ketorolac pills 1-hour vs 2-hours before an IUD decreases pain levels. We would need 3 hours of in-person clinic time from volunteers. Compensation provided.

Age & Gender
  • 18 years ~ 99 years
  • Female, Gender Inclusive
Study Interest
  • Healthy Volunteer or General Population
  • Sexual and/or Reproductive Health
  • Wellness and Lifestyle
  • Women's Health
Open

Inaxaplin in Subjects With Proteinuric APOL1-mediated Kidney Disease

If you have protein in the urine and African descent, Hispanic or American Indian you might have a gene call APOL1 contributing kidney disease. This study will test if you have change in the gene. If you do have that change you can participate in this study .

Age & Gender
  • 18 years ~ 67 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Pressure
  • Diabetes
  • Kidneys and Liver
Coming Soon

A study to investigate the safety and efficacy of IOV-3001 in adults with advanced (unresectable or metastatic) melanoma who will receive lifileucel

The purpose of this study is to find the maximum tolerated dose and the recommended Phase 2 dose of IOV-3001 infusion given after lifileucel to participants with advanced (unresectable or metastatic) melanoma who meet the requirements for treatment with lifileucel. The study duration for each participant will be up to about 6 months (Phase 1, Part 1) or 5 years (Phase 1, Part 2) after the lifileucel dose. Study intervention begins with surgery to get a tumor sample that will be used to make lifileucel

Age & Gender
  • 18 years ~ 70 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Melanoma)
Visit Location
Coming Soon

Gene Therapy Study for CD19 Positive Hematologic Malignancies

The main purpose of this study is to test the safety of a gene therapy. Scientists have created a gene in the laboratory that could be transferred to the cells in the body. This gene carries information to tell the cells how to make an antibody (protein). The antibody (protein) is very similar to an antibody (protein) called blinatumomab. Blinatumomab is an FDA-approved treatment for relapsed or refractory B-cell ALL. This gene therapy is not approved by the FDA, therefore is it experimental. This study tests different doses of the gene therapy to see which dose is safer in people since it has not been tested in people yet.

Age & Gender
  • 13 years ~ 90 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia, Lymphoma)
Open

Treatment trial for Major Depressive Disorder using non-invasive brain stimulation  

Do you have depression and are currently experiencing depression symptoms? We are conducting a treatment trial to see whether non-invasive brain stimulation that matches your brain waves can improve depression symptoms. This is a randomized controlled trial where participants will be randomly assigned to receive active or placebo (fake) stimulation. Compensation is provided.

Age & Gender
  • 18 years ~ 70 years
  • Male, Female, Gender Inclusive
Study Interest
  • Behavior
  • LGBTQIA+
  • UNC or UNC Health employees
  • and 3 more
Open

A Low-Dose Tamoxifen Trial for Early Breast Cancer

Do you have early-stage breast cancer that is considered low-risk by your doctor? If yes, you might be able to join a research study. In this study, we are testing if taking a lower dose of the medicine tamoxifen is a better treatment for you than the usual hormone therapy.

Age & Gender
  • 18 years ~ 99 years
  • Female
Study Interest
  • Cancer (Breast)
  • Women's Health
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research